Qiagen N.V. (QGEN)

Market Cap	9.85B
Revenue (ttm)	2.04B
Net Income (ttm)	373.39M
Shares Out	216.83M
EPS (ttm)	1.69
PE Ratio	26.83
Forward PE	18.89
Dividend	$1.51 (3.31%)
Ex-Dividend Date	Jul 2, 2025

Volume	959,558
Open	45.39
Previous Close	45.60
Day's Range	45.18 - 46.18
52-Week Range	37.63 - 51.88
Beta	0.64
Analysts	Buy
Price Target	51.01 (+12.31%)
Earnings Date	Nov 5, 2025

About QGEN

Qiagen N.V. provides sample to insight solutions that transform biological samples into molecular insights in the Netherlands and internationally. The company offers primary sample technology consumables, such as nucleic acid stabilization and purification kits for sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, such as kits and components for purification of nucleic acids; and...

• Industry: Diagnostics & Research
• Sector: Healthcare
• IPO Date: Jun 28, 1996
• Employees: 5,967
• Stock Exchange: NYSE
• Ticker Symbol: QGEN
• Website: https://www.qiagen.com

Financial Performance

In 2024, Qiagen's revenue was $1.98 billion, an increase of 0.66% compared to the previous year's $1.97 billion. Earnings were $83.59 million, a decrease of -75.51%.

Analyst Summary

According to 8 analysts, the average rating for QGEN stock is "Buy." The 12-month stock price target is $51.01, which is an increase of 12.31% from the latest price.

Price Target

$51.01

(12.31% upside)

Analyst Consensus: Buy